Gabriele Mocciaro, Amy L George, Michael Allison, Mattia Frontini, Isabel Huang-Doran, Frank Reiman, Fiona Gribble, Julian L Griffin, Antonio Vidal-Puig, Vian Azzu and 2 more
Article in Liver international : official journal of the International Association for the Study of the Liver, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
Gabriele MocciaroRoger Williams Institute of Liver Studies, Foundation for Liver Research, London, UK.ORCID 0000-0001-5392-0909
Amy L GeorgeInstitute of Metabolic Science Metabolic Research Laboratories, Addenbrooke's Hospital, Cambridge, UK.ORCID 0000-0002-6782-1626
Michael AllisonLiver Unit, Cambridge NIHR Biomedical Research Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Mattia FrontiniFaculty of Health and Life Sciences, Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, UK.
Isabel Huang-DoranInstitute of Metabolic Science Metabolic Research Laboratories, Addenbrooke's Hospital, Cambridge, UK.
Frank ReimanInstitute of Metabolic Science Metabolic Research Laboratories, Addenbrooke's Hospital, Cambridge, UK.
Fiona GribbleInstitute of Metabolic Science Metabolic Research Laboratories, Addenbrooke's Hospital, Cambridge, UK.
Julian L GriffinThe Rowett Institute, Foresterhill Campus, University of Aberdeen, Aberdeen, UK.
Antonio Vidal-PuigInstitute of Metabolic Science Metabolic Research Laboratories, Addenbrooke's Hospital, Cambridge, UK.
Vian AzzuInstitute of Metabolic Science Metabolic Research Laboratories, Addenbrooke's Hospital, Cambridge, UK.
Richard KayInstitute of Metabolic Science Metabolic Research Laboratories, Addenbrooke's Hospital, Cambridge, UK.
Michele VaccaRoger Williams Institute of Liver Studies, Foundation for Liver Research, London, UK.ORCID 0000-0002-1973-224X
Funding
British Heart Foundation FS/18/53/33863British Heart Foundation RE/18/1/34212Medical Research Council MC_UU_00014/5Medical Research Council MC UU 12012/3Medical Research Council MC UU12012/5Medical Research Council MR/M009041/1Medical Research Council MR/P011705/1Medical Research Council MR/P01836X/1Medical Research Council MR/S010483/1Medical Research Council MR/X012700/1This research was supported by NIHR Cambridge Biomedical Research Centre (BRC-1215-20014) funding to V.A., M.A., and M.V.The initial establishment of the cohorts was supported by the Evelyn Trust (funding to M.A. and A.V.P.), Mason Medical Research Trust (funding to V.A.), and the Academy of Medical Sciences (funding to V.A.). V.A. was supported by the University of Cambridge. M.A. is supported by Cambridge University Hospitals NHS Foundation Trust. M.V. is supported by the University of Bari (Horizon Europe Seed cod. id. S06-miRNASH), the Foundation for Liver Research (Intramural Funding), Associazione Italiana Ricerca sul Cancro (IG2022 Grant n. 27521) and Ministry of University and Research on Next Generation EU Funds [COD: P202222FCC, CUP: H53D23009960001, D.D. MUR 1366 (01-09-2023), Title: "System Biology" approaches in HCV Patients with Residual Hepatic Steatosis after Viral Eradication; Cod PE00000003, CUP: H93C22000630001, DD MUR 1550, Title: "ON Foods - Research and innovation network on food and nutrition Sustainability, Safety and Security - Working ON Foods"; Cod: CN00000041, CUP: H93C22000430007, Title PNRR "National Center for Gene Therapy and Drugs based on RNA Technology", M4C2-Investment 1.4; Code: CN00000013, CUP: H93C22000450007, Title PNNR: "National Centre for HPC, Big Data and Quantum Computing").A.V.P. is funded by MRC MDU, MRC Metabolic Diseases Unit (MC_UU_00014/5): Disease Model Core, Biochemistry Assay Lab, Histology Core and British Heart Foundation. M.F. is supported by the British Heart Foundation (FS/18/53/33863) and the British Heart Foundation Cambridge Centre for Research Excellence (RE/18/1/34212). This study was supported by the National Institute for Health and Care Research Exeter Biomedical Research Centre. We would like to thank all participants in this study and the NIHR National BioResource. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. JLG is funded by the Medical Research Council (MR/S010483/1; MR/P011705/1; MR/P01836X/1; MR/X012700/1). F.G., F.R., R.K. and A.L.G. were funded by the Wellcome Trust (grants 106262/Z/14/Z, 106263/Z/14/Z), the MRC Metabolic Diseases Unit (grants MRC MC UU 12012/3, MRC MC UU12012/5) and by the NIHR Cambridge Biomedical Research Centre. The mass spectrometers were obtained using the Medical Research Council "Enhancing UK Clinical Research" grant (MR/M009041/1). The views expressed are those of the author(s) and not necessarily those of the relevant funding or supporting institutions. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscriptWellcome TrustWellcome Trust 106262/Z/14/ZWellcome Trust 106263/Z/14/Z
6 · The paper itself
Abstract
backgroundMetabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) encompasses a spectrum of histological conditions ranging from simple steatosis to fibrosing steatohepatitis, and is a risk factor for cardiovascular diseases (CVD). While oxidised apolipoproteins A and B have been linked to obesity and CVD, the association between other oxidised apolipoproteins and MASLD is yet to be established. To fill this gap, we characterised the circulating serum peptidome of patients with MASLD.
methodsWe studied the serum of 87 biopsy-confirmed MASLD patients and 20 age- and sex-matched control (CTRL) subjects. We first employed an untargeted LC-MS/MS peptidomics approach (9 CTRL, 32 MASLD) to identify key hits differentially modulated, and subsequently validated the most relevant findings through targeted peptidomics in an enlarged study population (87 MASLD and 20 CTRL).
resultsUntargeted serum peptidomics identified several oxidised apolipoprotein peptide fragments, including ApoE and ApoC-III, significantly upregulated in MASLD compared to CTRL. Specifically focusing on the oxidative status of intact ApoC-III, studied through its major glycoforms (ApoC-III
conclusionOur data reveals a previously unreported oxidised apolipoprotein profile associated with MASLD. The functional and clinical implications of these findings warrant further mechanistic investigation.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.